Document is current
Any future updates will be listed below
-
Authors
Li, Roger https://orcid.org/0000-0003-1274-7200
Villa, Nancy Y.
Yu, Xiaoqing https://orcid.org/0000-0003-4585-9372
Johnson, Joseph O.
Borjas, Gustavo https://orcid.org/0000-0002-8857-0299
Dhillon, Jasreman https://orcid.org/0000-0001-6785-3487
Moran-Segura, Carlos M. https://orcid.org/0000-0001-8702-0554
Kim, Youngchul
Francis, Natasha
Dorman, Denise
Powers, John J. https://orcid.org/0000-0003-3800-2645
Sexton, Wade J.
Spiess, Philippe E.
Poch, Michael A.
Zemp, Logan
Gilbert, Scott M.
Zhang, Jingsong https://orcid.org/0000-0003-1192-5116
Pow-Sang, Julio M.
Anderson, Alexander R. A. https://orcid.org/0000-0002-2536-4383
Li, Tingyi
Wang, Xuefeng https://orcid.org/0000-0001-5775-408X
Grass, G. Daniel
Burke, James M.
Dinney, Colin P. N.
Rodriguez, Paulo C. https://orcid.org/0000-0001-7480-6566
Jain, Rohit K.
Mulé, James J. https://orcid.org/0000-0001-7354-0516
Conejo-Garcia, Jose R. https://orcid.org/0000-0001-6431-4074
-
Funding
Funding for this research was provided by:
U.S. Department of Defense (W81XWH-22-1-0395)
CG Oncology, Moffitt Cancer Center, Campbell Family Foundation
- License Information
-
More Information
Article History
Received: 14 January 2024
Accepted: 27 September 2024
First Online: 9 November 2024
Competing interests
: R.L. reports research support from Predicine, Veracyte, CG Oncology, Valar Labs, Merck and Janssen; clinical trial protocol committee participation with CG Oncology, Merck and Janssen; and is scientific advisor/consultant for Bristol Myers Quibb, Merck, Fergene, Arquer Diagnostics, Urogen Pharma, Lucence, CG Oncology, Janssen, Thericon, Iconovir, ImmunityBio and Pfizer. W.J.S. reports consultant work for Pacific Edge and Urogen Pharma. P.E.S. reports being the Vice Chair of the NCCN guidelines committee for bladder and penile cancer. J.Z. reports consultant work for Sanofi, AstraZeneca, Dendreon, Seagen, Bayer and Pfizer. G.D.G. reports consultant work for MyCareGorithm and stock options in Lantheus. J.M.B. reports consultant work for CG Oncology and Kalivir Immunotherapeutics and being a shareholder of CG Oncology and Kalivir Immunotherapeutics. C.P.N.D. reports consultant work for AstraZeneca and CG Oncology and intellectual property ownership related to the use of genetic alterations as a predictive biomarker for response to nadofaragene firadenovec. R.K.J. reports consultant work for AVEO, Bristol Myers Squibb, Sanofi, EMD Serono, Gilead Sciences, IDEOlogy Pfizer and Seattle Genetics/Astellas; speaker’s bureau for Gilead Sciences, Seagen and Seattle Genetics/Astellas; research funding from Bristol Myers Squibb, Gilead Sciences and the National Cancer Institute; and honoraria from FLASCO, Curio Science, DAVA Oncology, NCCN/Pfizer and OncLive/MJH Life Sciences. J.J.M. reports membership on the CG Oncology Board of Directors; being the Associate Center Director at Moffitt Cancer Center; ownership interest in Aleta Biotherapeutics, CG Oncology, Turnstone Biologics, Ankyra Therapeutics and AffyImmune Therapeutics; and consultant work for ONCoPEP, CG Oncology, Turnstone Biologics, Vault Pharma, Ankyra Therapeutics, AffyImmune Therapeutics, UbiVac, Vycellix and Aleta Biotherapeutics. J.R.C.-G. reports consultant work for Anixa Biosciences and Alloy Therapeutics; stock options in Compass Therapeutics, Anixa Biosciences and Alloy Therapeutics; patent licensed by Anixa Biosciences; intellectual property filed with Compass Therapeutics; and being the co-founder of Cellepus Therapeutics, a CAR T cell company. The other authors declare no competing interests.
